Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb;47(2):212-214.
doi: 10.1177/17531934211022164. Epub 2021 Jun 9.

Surgical treatment of symptomatic neuromas: a feasibility study using the NEUROCAP® bioresorbable nerve capping device

Edwin L de Vrij  1 , Tim R Schäfer  1 , Tom van Mulken  2 , Mariëtta J O E Bertleff  3
Affiliations

Surgical treatment of symptomatic neuromas: a feasibility study using the NEUROCAP® bioresorbable nerve capping device

Edwin L de Vrij et al. J Hand Surg Eur Vol. 2022 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interests: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: MB was involved in device conception under patent EP3265142 / US20180339083. All participating surgeons (TS, TvM, MB) were contracted as investigator for the study. EdV declares to have no conflicting interests with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
The NEUROCAP® device.
Figure 2.
Figure 2.
Pain reduction over time after neuroma excision and capping with NEUROCAP® as determined by visual analogue scale (VAS), Douleur Neuropathique 4 (DN4) questionnaire and neuroma pain score. Dotted grey line represents the time of treatment. Measurements at all time points were for 10 patients, except for 6 and 12 months (n = 9). Data represented as estimated marginal means with standard deviation. *: P < 0.05 compared with preoperative baseline, generalized estimated equations using an unstructured working correlation matrix structure; Mo: months.
Figure 3.
Figure 3.
Functional improvement of upper limb after neuroma excision and capping with NEUROCAP®, as measured by Quick Disabilities of the Arm, Shoulder and Hand (QuickDASH) questionnaire. Dotted grey line represents moment of treatment. Measurements at all time points were for 10 patients, except for 6 and 12 months (n = 9). Data represented as estimated marginal means with standard deviation. *: P < 0.05 compared with preoperative baseline; #: P < 0.05 compared with 6 weeks follow-up, generalized estimated equations using an unstructured working correlation matrix structure; Mo: months.
See this image and copyright information in PMC

References

    1. Elliot D, Lloyd M, Hazari A et al. Relief of the pain of neuromas-in-continuity and scarred median and ulnar nerves in the distal forearm and wrist by neurolysis, wrapping in vascularized forearm fascial flaps and adjunctive procedures. J Hand Surg Eur Vol. 2010, 35: 575--82. - PubMed
    1. George S, Pohl U, Power D. Analysis of an end neuroma 6 months after capping with a bioresorbable polycaprolactone cap (NEUROCAP®) in a human model. Surg Case Rep. 2020, 3: 2–4.
    1. Regal S, Tang P. Surgical management of neuromas of the hand and wrist. J Am Acad Orthop Surg. 2019, 27: 356–63. - PubMed
    1. van der Avoort DJ, Hovius SE, Selles RW, et al.. The incidence of symptomatic neuroma in amputation and neurorrhaphy patients. J Plast Reconstr Aesthet Surg. 2013, 66: 1330–4. - PubMed
    1. Yan H, Zhang F, Kolkin J, et al.. Mechanisms of nerve capping technique in prevention of painful neuroma formation. PLoS One. 2014, 9: e93973. - PMC - PubMed

LinkOut - more resources